title: Complete resolution of erythrodermic psoriasis in an HIV and HCV patient unresponsive to antipsoriatic treatments after highly active antiretroviral therapy (Ritonavir, Atazanavir, Emtricitabine, Tenofovir).
abstract: BACKGROUND
  Psoriasis is a chronic, inflammatory disease affecting 2-3% of the worldwide population, and it may worsen with HIV or be detected as HIV cutaneous manifestation. HIV-related psoriasis shows a severe and prolonged clinical course with more frequent exacerbations. The management of this condition is challenging because immunomodulating and immunosuppressant agents may have variable and partial efficacy, and therefore, antiretroviral treatment represents a potential adjunctive therapeutic option.
  
  
  RESULTS
  In the case we report, the HIV test was shown to be crucial for driving the therapeutic approach. Indeed, antiretroviral agents have been proven to be effective in the treatment of HIV+ psoriasis as first-line therapy.
  
  
  CONCLUSIONS
  The HIV test should be considered in high-risk patients affected by severe psoriasis and resistant to conventional and biological treatments.
authors.affiliation: Department of Dermatology, University of Rome 'Tor Vergata', Rome, Italy. chiricozziandrea@gmail.com
authors.forename: Andrea
authors.initials: A
authors.lastname: Chiricozzi
authors.forename: Rosita
authors.initials: R
authors.lastname: Saraceno
authors.forename: Maria Vittoria
authors.initials: MV
authors.lastname: Cannizzaro
authors.forename: Steven P
authors.initials: SP
authors.lastname: Nisticò
authors.forename: Sergio
authors.initials: S
authors.lastname: Chimenti
authors.forename: Alessandro
authors.initials: A
authors.lastname: Giunta
mesh_terms: D000225:Adenine / Q000031:analogs & derivatives / Q000627:therapeutic use; D019380:Anti-HIV Agents / Q000627:therapeutic use*; D023241:Antiretroviral Therapy, Highly Active; D000069446:Atazanavir Sulfate; D003841:Deoxycytidine / Q000031:analogs & derivatives / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D000068679:Emtricitabine; D015658:HIV Infections / Q000150:complications / Q000188:drug therapy*; D019698:Hepatitis C, Chronic / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D016867:Immunocompromised Host; D008297:Male; D008875:Middle Aged; D009842:Oligopeptides / Q000627:therapeutic use; D063065:Organophosphonates / Q000627:therapeutic use; D011565:Psoriasis / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D011725:Pyridines / Q000627:therapeutic use; D019438:Ritonavir / Q000627:therapeutic use; D000068698:Tenofovir; D016896:Treatment Outcome
chemical_list: D019380:Anti-HIV Agents; D009842:Oligopeptides; D063065:Organophosphonates; D011725:Pyridines; D003841:Deoxycytidine; D000069446:Atazanavir Sulfate; D000068698:Tenofovir; D000068679:Emtricitabine; D000225:Adenine; D019438:Ritonavir